1. Off-target assessment of CRISPR-Cas9 guiding RNAs in human iPS and mouse ES cells.

    Genesis 53(2):225 (2015) PMID 25378133

    The CRISPR-Cas9 system consists of a site-specific, targetable DNA nuclease that holds great potential in gene editing and genome-wide screening applications. To apply the CRISPR-Cas9 system to these assays successfully, the rate at which Cas9 induces DNA breaks at undesired loci must be underst...
  2. Off-target assessment of CRISPR-Cas9 guiding RNAs in human iPS and mouse ES cells.

    Genesis 53(2):225 (2015) PMID 25378133

    The CRISPR-Cas9 system consists of a site-specific, targetable DNA nuclease that holds great potential in gene editing and genome-wide screening applications. To apply the CRISPR-Cas9 system to these assays successfully, the rate at which Cas9 induces DNA breaks at undesired loci must be underst...
  3. A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer.

    Nature Genetics 47(1):47 (2015) PMID 25485836

    Here we describe a conditional piggyBac transposition system in mice and report the discovery of large sets of new cancer genes through a pancreatic insertional mutagenesis screen. We identify Foxp1 as an oncogenic transcription factor that drives pancreatic cancer invasion and spread in a mouse...
  4. A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer.

    Nature Genetics 47(1):47 (2015) PMID 25485836

    Here we describe a conditional piggyBac transposition system in mice and report the discovery of large sets of new cancer genes through a pancreatic insertional mutagenesis screen. We identify Foxp1 as an oncogenic transcription factor that drives pancreatic cancer invasion and spread in a mouse...
  5. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  6. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  7. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  8. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  9. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  10. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  11. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  12. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  13. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  14. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  15. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  16. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  17. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  18. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  19. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...
  20. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

    Nature Medicine 20(11):1340 (2014) PMID 25326799 PMCID PMC4270133

    Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have dev...